Literature DB >> 11121398

Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury.

J Lohi1, C L Wilson, J D Roby, W C Parks.   

Abstract

We have cloned a new human matrix metalloproteinase (MMP-28, epilysin) from human keratinocyte and testis cDNA libraries. Like most MMPs, epilysin contains a signal sequence, a prodomain with a PRCGVTD sequence, a zinc-binding catalytic domain with an HEIGHTLGLTH sequence, and a hemopexin-like domain. In addition, epilysin has a furin activation sequence (RRKKR) but has no transmembrane sequence. The exon-intron organization and splicing pattern of epilysin differ from that of other MMP genes. It has only 8 exons, and 5 exons are spliced at sites not used by other MMPs. Another novel feature of epilysin is that exon 4 is alternatively spliced to a transcript that does not encode the N-terminal half of the catalytic domain. Northern hybridization of tissue RNA indicated that epilysin is expressed at high levels in testis and at lower levels in lungs, heart, colon, intestine, and brain. RNase protection assay with various cell lines indicated that epilysin was selectively expressed in keratinocytes. Recombinant epilysin degraded casein in a zymography assay, and its proteolytic activity was inhibited by EDTA and by batimastat, a selective MMP inhibitor. Immunohistochemical staining showed expression of epilysin protein in the basal and suprabasal epidermis of intact skin. In injured skin, prominent staining for epilysin was seen in basal keratinocytes both at and some distance from the wound edge, a pattern that is quite distinct from that of other MMPs expressed during tissue repair. These findings suggest that this new MMP functions in several tissues both in tissue homeostasis and in repair.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121398     DOI: 10.1074/jbc.M001599200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 2.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

Review 3.  MMPs and TIMPs--an historical perspective.

Authors:  J Frederick Woessner
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

4.  Gelatin-based anionic hydrogel as biocompatible substrate for human keratinocyte growth.

Authors:  Filippo Renò; Manuela Rizzi; Mario Cannas
Journal:  J Mater Sci Mater Med       Date:  2011-12-13       Impact factor: 3.896

5.  Prediction of metalloproteinase family based on the concept of Chou's pseudo amino acid composition using a machine learning approach.

Authors:  Majid Mohammad Beigi; Mohaddeseh Behjati; Hassan Mohabatkar
Journal:  J Struct Funct Genomics       Date:  2011-12-03

Review 6.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 7.  Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.

Authors:  Merry L Lindsey; Rugmani Padmanabhan Iyer; Mira Jung; Kristine Y DeLeon-Pennell; Yonggang Ma
Journal:  J Mol Cell Cardiol       Date:  2015-12-23       Impact factor: 5.000

Review 8.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 9.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 10.  Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted.

Authors:  Kendra J Greenlee; Zena Werb; Farrah Kheradmand
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.